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Appendix 1 
The nevirapine model presented in Figure 1 is explained in detail below. 2 
The delay between oral administration and absorption is modelled through 2 transit compartments. 3 
After entering the absorption compartment, nevirapine is transferred to the liver, where it 4 
undergoes 1st-pass hepatic extraction (EH). The fraction of the drug not eliminated by 1st-pass (1-EH) 5 
is then transported via hepatic plasma flow (QH) to the central compartment and the systemic 6 
circulation. It then recirculates back to the liver, which is the site of drug clearance. In this well-7 
stirred model, hepatic clearance (CLH) is determined by QH and EH as follows: 8 
(1)     9 
EH depends on the unbound fraction of the drug (fu), liver activity (CLint), and QH and is defined as: 10 
(2)      11 
EH also determines the hepatic bioavailability FH 12 
(3)    13 
The total oral bioavailability (F) is determined by both the pre-hepatic (FpreH) and hepatic (FH) 14 
components, as follows: 15 
(4)      16 
After a number of transformations, oral clearance can be simplified as follows:  17 
(5)     18 
Due to circadian rhythm variations, CLint changes with time, thus affecting both CLH and FH, and its 19 
value at time (t) is defined as follows: 20 
(6)     21 
where AMP is the amplitude of the cosine oscillation and SHIFT is the phase shift of the cosine 22 
function relative to 00:00. In order to prevent negative values of CLint the effect of the circadian 23 
rhythm was modelled as exponential and can be interpreted approximately as a relative change. 24 
Furthermore, FpreH changes with age, as expressed by following equation: 25 
(7)     26 
where FpreH_BIRTH is the FpreH at birth, KFpreH is the rate constant for age-driven change in FpreH and AGE 27 
refers to age.  28 
29 
 30 
Table  S1. Observed Frequencies of Tested Single Nucleotide Polymorphisms with Corresponding 
Hardy-Weinberg P-values 
Gene SNP Hom-Ref† Het-LOF† Hom-LOF† MAF 
HWE 
P-value 
CYP2B6 
rs3745274 
(516G>T) 
GG GT TT 
0.36 0.18 
136 (0.43) 136 (0.43) 47 (0.15) 
rs28399499 
(983T>C) 
TT TC CC 
0.09 1 
226 (0.83) 51 (0.16) 2 (0.01) 
rs4803419 
(15582C>T) 
CC TC TT 
0.07 0.19 
227 (0.87) 39 (0.12) 3 (0.01) 
CYP3A4 
rs35599367 
(CYP3A4*22) 
GG GA AA 
0.003 1 
317 (0.99) 2 (0.01) 0 
CYP3A5 
rs776746 
(6986G>A) 
GG GA AA 
0.82 0.44 
12 (0.04) 88 (0.28) 219 (0.69) 
NR1I3 
(CAR) 
rs3003596 
AA AG GG 
0.49 1 
78 (0.24) 159 (0.50) 82 (0.26) 
rs2307424 
(540C>T) 
CC CT TT 
0.08 0.42 
272 (0.85) 44 (0.14) 3 (0.01) 
NR1I2 
(PXR) 
rs2472677 
(63396C>T) 
CC CT TT 
0.36 0.14 
124 (0.39) 160 (0.50) 35 (0.11) 
ABCC10 rs2125739 
TT CT CC 
0.23 0.27 
185 (0.58) 120 (0.38) 13 (0.04) 
 31 
†number (proportion). Hom-Ref - homozygous for the functional allele; Het-LOF - heterozygous for 32 
the loss-of-function (LOF) allele; Hom-LOF - homozygous for the LOF allele; MAF – minor allele 33 
frequency; HWE - Hardy-Weinberg equilibrium. 34 
Note: information for 319 children from CHAPAS-3 study (aside from rs2125739 – data on 318 35 
children). 36 
 37 
Table S2. Model estimated clearance intrinsic and corresponding hepatic clearance, 
hepatic extraction, hepatic bioavailability and oral clearance by metaboliser status. 
Metabolizer Status 
CLint 
[L/h] 
CLH 
[L/h] 
EH FH 
CLoral 
[L/h] 
Fast 3.27 1.20 7.9% 91.1% 1.29 
Intermediate 2.72 1.01 6.6% 93.4% 1.09 
Slow 1.65 0.63 4.1% 95.9% 0.68 
Very slow 1.04 0.40 2.6% 96.4% 0.43 
 38 
CLint – clearance intrinsic; CLH – clearance hepatic; EH – hepatic extraction; FH – hepatic component of 39 
bioavailability; CLoral – oral clearance 40 
Note: The relationship between parameters and how they can be derived explained in the Appendix. 41 
Presented values relate to an average child of 14.5 kg, 4.1 years of age and corresponding pre-42 
hepatic bioavailability of 93% and hepatic plasma flow of 15.35 (L/h). 43 
44 
 45 
 46 
 47 
Figure S1. Goodness of fit plots. Top left – observations vs population predictions (log scale); top 48 
right – observations vs individual predictions (log scale); bottom left – absolute values of individual 49 
weighted residuals vs individual predictions bottom right – conditional weighted residuals (CWRESI) 50 
vs time after dose;  51 
 52 
53 
 54 
Figure S2. Results of simulations evaluating the effect of intake time on nevirapine exposures (see 55 
Methods): (a) concentration-time curves for evaluated intake time scenarios; (b) differences 56 
between morning and evening Cmin depending on intake time; (c) differences between morning and 57 
evening AUC depending on intake time.  58 
59 
 60 
Figure S3. Nevirapine exposures obtained using different dose-splitting strategies (see Methods): (a) 61 
concentration-time curves for the evaluated dosing scenarios; (b) differences between morning and 62 
evening Cmin depending on dose-splitting strategy; (c) differences between morning and evening AUC 63 
depending on dose-splitting strategy.  64 
 65 
